Headlands Technologies LLC Takes $271,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Headlands Technologies LLC purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 11,934 shares of the life sciences company’s stock, valued at approximately $271,000.

Other institutional investors have also recently made changes to their positions in the company. Cannell & Spears LLC purchased a new stake in shares of Integra LifeSciences during the 4th quarter worth $3,555,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Integra LifeSciences by 7.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after buying an additional 913 shares during the last quarter. Orion Portfolio Solutions LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $728,000. Norges Bank purchased a new position in shares of Integra LifeSciences in the 4th quarter worth approximately $8,967,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Integra LifeSciences by 130.5% during the 4th quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company’s stock worth $4,529,000 after acquiring an additional 113,061 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Stock Down 2.4 %

Integra LifeSciences stock opened at $19.57 on Friday. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $34.79. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -217.42, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The business’s 50-day moving average price is $23.37 and its 200 day moving average price is $22.27. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.89 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.